In a landmark discovery, Fudan University's research team has identified a novel therapeutic target for Parkinson's disease (PD), marking a significant leap forward in the fight against this debilitating condition. Published in the prestigious journal Science, the study reveals FAM171A2, a neuronal membrane protein, as a key receptor for pathological α-synuclein, a protein central to PD progression. This breakthrough, the first of its kind globally, offers a potential pathway to slow or even halt the disease's progression.
Parkinson's disease, the second most common neurodegenerative disorder after Alzheimer's, affects over 10 million people worldwide, with half of the cases in China alone. Current treatments focus on symptom management but fail to address the underlying disease mechanisms. The discovery of FAM171A2 provides a new target for early intervention, potentially preventing the spread of pathological α-synuclein, which leads to neuronal death and the worsening of symptoms.
Using cutting-edge AI-driven screening techniques, the team analyzed over 7,000 compounds and identified bemcentinib, a small molecule that effectively blocks the interaction between FAM171A2 and α-synuclein. Animal studies demonstrated that inhibiting FAM171A2 significantly reduces PD-like symptoms, paving the way for the development of targeted therapies.
This groundbreaking research, led by Professor Yu Jintai and his team at Huashan Hospital, has been hailed as a "holy grail" in PD studies by Science reviewers. Beyond Parkinson's, the findings hold promise for other neurodegenerative diseases, such as Alzheimer's and Lewy body dementia, where α-synuclein plays a role.
With an international patent already filed, the team is now advancing toward clinical trials, focusing on small-molecule drugs, antibodies, and gene therapies targeting FAM171A2. This discovery not only highlights China's growing leadership in biomedical research but also brings hope to millions of patients and families affected by Parkinson's disease worldwide.
This breakthrough underscores the importance of continued investment in scientific research and collaboration, offering a glimpse of a future where neurodegenerative diseases can be effectively treated or even prevented.
